Welcome to our dedicated page for Oddity Tech Ltd. news (Ticker: ODD), a resource for investors and traders seeking the latest updates and insights on Oddity Tech Ltd. stock.
ODDITY Tech Ltd. (NASDAQ: ODD) is a consumer tech company that builds and scales digital-first brands in beauty, wellness and telehealth. Its AI-driven online platform serves approximately 60 million users and underpins brands such as IL MAKIAGE, SpoiledChild and METHODIQ.
The ODDITY news feed highlights the company’s regular financial updates, including quarterly earnings releases furnished on Form 6-K. These announcements cover net revenue, gross margin, net income, adjusted EBITDA, adjusted net income and adjusted diluted EPS, along with cash and investment balances and forward-looking financial outlooks.
Investors following ODDITY news can track developments such as the launch and expansion of METHODIQ, a medical telehealth platform focused on dermatology, and ongoing investment in ODDITY Labs, the company’s biotechnology and molecule discovery lab in Boston. News items also include capital markets activity, such as the pricing of exchangeable senior notes by Oddity Finance LLC, a wholly owned indirect subsidiary, and block trades of Class A ordinary shares by major shareholders.
Corporate governance and regulatory milestones appear in the news flow as well, including notices of upcoming earnings calls, details of the Annual General Meeting of Shareholders in Israel, and the furnishing of proxy materials. For anyone researching ODD stock, this page offers a centralized view of ODDITY’s financial performance, brand launches, capital structure updates and key corporate events over time.
Summary not available.
ODDITY Tech (NASDAQ: ODD) announced a $200 million share buyback plan approved by its Board on March 12, 2026. The Buyback Plan replaces a prior $150 million program and will expire on March 31, 2029 or when funds are fully deployed.
Oddity previously repurchased approximately $97 million under the prior authorization, including about $50 million year-to-date. Repurchases may occur in the open market, via Rule 10b5-1 plans, or in privately negotiated transactions, and the plan does not obligate the company to repurchase any specific number of shares.
ODDITY Tech (NASDAQ: ODD) reported record 2025 results with $810M full year net revenue, up 25% YoY, and fourth quarter net revenue of $153M, up 24% YoY. Full year adjusted EBITDA was $163M and cash, equivalents and investments totaled $776M.
Management flagged an advertising partner dislocation that raised new user acquisition costs and expects Q1 2026 revenue to decline ~30% YoY, while retaining a $103M remaining buyback authorization.
ODDITY (NASDAQ: ODD) will release its fourth quarter and full year 2025 financial results before market open on February 25, 2026, followed by a conference call at 8:30 a.m. ET.
According to the company, a live webcast and dial-in access are available, with a replay archived on the investor website for seven days. Replay access code: 13758683.
ODDITY (NASDAQ: ODD) reported record third quarter results for the period ended September 30, 2025, with Q3 net revenue $148M (+24% YoY) and nine-month net revenue $657M (+26% YoY). Q3 gross profit was $106M and gross margin improved to 71.6% (+170 bps). Q3 adjusted EBITDA was $29M and nine-month adjusted EBITDA was $151M. Q3 net income was $18M and adjusted net income was $25M (+26% YoY). Cash, equivalents and investments totaled $793M with $200M undrawn credit facilities as of Sept. 30, 2025. The company raised full-year 2025 outlook to $806–809M revenue, gross margin ~72.5%, adjusted EBITDA $161–163M, and adjusted diluted EPS $2.10–2.12. METHODIQ brand formally launched in November 2025.
ODDITY (NASDAQ: ODD) launched METHODIQ on November 18, 2025, a telehealth platform delivering AI-driven, prescription and OTC dermatology care entirely online.
METHODIQ debuts with dermatology for acne, hyperpigmentation and eczema, a portfolio of 28 core products and >100 personalized treatment plans, backed by four years of development and large-scale consumer studies. The platform uses proprietary computer-vision models trained on >1 million clinical images for progress tracking and weekly clinician-adjusted care. ODDITY says METHODIQ aims to expand into other medical domains and leverage its ~60 million user base.
ODDITY (NASDAQ: ODD) will release its third quarter 2025 financial results after market close on November 19, 2025. A conference call is scheduled for November 20, 2025 at 8:30 a.m. ET. Investors can join by phone (US: 1-877-407-9208; international: 1-201-493-6784) and should reference ODDITY Third Quarter 2025 Earnings Call. A live webcast will be available at https://investors.oddity.com and an archive will remain on the site for seven days after the call. A phone replay will be accessible (US: 1-844-512-2921; international: 1-412-317-6671) using access code 13755969.
ODDITY Tech (NASDAQ: ODD) reported strong Q2 2025 results, with net revenue reaching $241 million, up 25% year-over-year. The company achieved $70 million in adjusted EBITDA and $49 million in net income.
Key financial metrics include a 72.3% gross margin, adjusted diluted EPS of $0.92, and a robust cash position of $815 million. The company raised its full-year 2025 outlook, projecting revenue between $799-804 million (23-24% growth) and adjusted EBITDA of $160-162 million.
Strategic developments include double-digit growth for IL MAKIAGE and SpoiledChild, international expansion, and progress on Brand 3 launch in Q4 2025. The company completed a $600 million exchangeable note offering with 0% coupon and maintains $200 million in undrawn credit facilities.
ODDITY Tech (NASDAQ: ODD) has scheduled its second quarter 2025 financial results announcement for August 4, 2025 after market close. The company will host a conference call to discuss the results on August 5, 2025, at 8:30 a.m. ET.
Investors can access the conference call by dialing 1-800-717-1738 (US) or 1-646-307-1865 (international). A webcast will be available on ODDITY's investor relations website, and a replay can be accessed using code 1106918.